Cargando…

Kaposi’s Sarcoma-Associated Herpesvirus Drives a Super-Enhancer-Mediated Survival Gene Expression Program in Primary Effusion Lymphoma

Kaposi’s sarcoma-associated herpesvirus (KSHV) causes primary effusion lymphoma (PEL). The cellular transcription factor (TF) interferon (IFN) regulatory factor 4 (IRF4) is an essential oncogene in PEL, but its specific role in PEL and how KSHV deregulates IRF4 remain unknown. Here, we report that t...

Descripción completa

Detalles Bibliográficos
Autores principales: Manzano, Mark, Günther, Thomas, Ju, Hyunwoo, Nicholas, John, Bartom, Elizabeth T., Grundhoff, Adam, Gottwein, Eva
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Society for Microbiology 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7448273/
https://www.ncbi.nlm.nih.gov/pubmed/32843547
http://dx.doi.org/10.1128/mBio.01457-20
_version_ 1783574469237800960
author Manzano, Mark
Günther, Thomas
Ju, Hyunwoo
Nicholas, John
Bartom, Elizabeth T.
Grundhoff, Adam
Gottwein, Eva
author_facet Manzano, Mark
Günther, Thomas
Ju, Hyunwoo
Nicholas, John
Bartom, Elizabeth T.
Grundhoff, Adam
Gottwein, Eva
author_sort Manzano, Mark
collection PubMed
description Kaposi’s sarcoma-associated herpesvirus (KSHV) causes primary effusion lymphoma (PEL). The cellular transcription factor (TF) interferon (IFN) regulatory factor 4 (IRF4) is an essential oncogene in PEL, but its specific role in PEL and how KSHV deregulates IRF4 remain unknown. Here, we report that the KSHV latency protein viral interferon regulatory factor 3 (vIRF3) cooperates with IRF4 and cellular BATF (basic leucine zipper ATF-like TF) to drive a super-enhancer (SE)-mediated oncogenic transcriptional program in PEL. Chromatin immunoprecipitation coupled with next-generation sequencing (ChIP-Seq) experiments demonstrated that IRF4, vIRF3, and BATF cooccupy the SEs of key survival genes, in a pattern that is distinct from those seen with other IRF4-driven malignancies. All three proteins cooperatively drive SE-mediated IRF4 overexpression. Inactivation of vIRF3 and, to a lesser extent, BATF phenocopies the gene expression changes and loss of cellular viability observed upon inactivation of IRF4. In sum, this work suggests that KSHV vIRF3 and cellular IRF4 and BATF cooperate as oncogenic transcription factors on SEs to promote cellular survival and proliferation in KSHV-associated lymphomas.
format Online
Article
Text
id pubmed-7448273
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher American Society for Microbiology
record_format MEDLINE/PubMed
spelling pubmed-74482732020-09-02 Kaposi’s Sarcoma-Associated Herpesvirus Drives a Super-Enhancer-Mediated Survival Gene Expression Program in Primary Effusion Lymphoma Manzano, Mark Günther, Thomas Ju, Hyunwoo Nicholas, John Bartom, Elizabeth T. Grundhoff, Adam Gottwein, Eva mBio Research Article Kaposi’s sarcoma-associated herpesvirus (KSHV) causes primary effusion lymphoma (PEL). The cellular transcription factor (TF) interferon (IFN) regulatory factor 4 (IRF4) is an essential oncogene in PEL, but its specific role in PEL and how KSHV deregulates IRF4 remain unknown. Here, we report that the KSHV latency protein viral interferon regulatory factor 3 (vIRF3) cooperates with IRF4 and cellular BATF (basic leucine zipper ATF-like TF) to drive a super-enhancer (SE)-mediated oncogenic transcriptional program in PEL. Chromatin immunoprecipitation coupled with next-generation sequencing (ChIP-Seq) experiments demonstrated that IRF4, vIRF3, and BATF cooccupy the SEs of key survival genes, in a pattern that is distinct from those seen with other IRF4-driven malignancies. All three proteins cooperatively drive SE-mediated IRF4 overexpression. Inactivation of vIRF3 and, to a lesser extent, BATF phenocopies the gene expression changes and loss of cellular viability observed upon inactivation of IRF4. In sum, this work suggests that KSHV vIRF3 and cellular IRF4 and BATF cooperate as oncogenic transcription factors on SEs to promote cellular survival and proliferation in KSHV-associated lymphomas. American Society for Microbiology 2020-08-25 /pmc/articles/PMC7448273/ /pubmed/32843547 http://dx.doi.org/10.1128/mBio.01457-20 Text en Copyright © 2020 Manzano et al. https://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution 4.0 International license (https://creativecommons.org/licenses/by/4.0/) .
spellingShingle Research Article
Manzano, Mark
Günther, Thomas
Ju, Hyunwoo
Nicholas, John
Bartom, Elizabeth T.
Grundhoff, Adam
Gottwein, Eva
Kaposi’s Sarcoma-Associated Herpesvirus Drives a Super-Enhancer-Mediated Survival Gene Expression Program in Primary Effusion Lymphoma
title Kaposi’s Sarcoma-Associated Herpesvirus Drives a Super-Enhancer-Mediated Survival Gene Expression Program in Primary Effusion Lymphoma
title_full Kaposi’s Sarcoma-Associated Herpesvirus Drives a Super-Enhancer-Mediated Survival Gene Expression Program in Primary Effusion Lymphoma
title_fullStr Kaposi’s Sarcoma-Associated Herpesvirus Drives a Super-Enhancer-Mediated Survival Gene Expression Program in Primary Effusion Lymphoma
title_full_unstemmed Kaposi’s Sarcoma-Associated Herpesvirus Drives a Super-Enhancer-Mediated Survival Gene Expression Program in Primary Effusion Lymphoma
title_short Kaposi’s Sarcoma-Associated Herpesvirus Drives a Super-Enhancer-Mediated Survival Gene Expression Program in Primary Effusion Lymphoma
title_sort kaposi’s sarcoma-associated herpesvirus drives a super-enhancer-mediated survival gene expression program in primary effusion lymphoma
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7448273/
https://www.ncbi.nlm.nih.gov/pubmed/32843547
http://dx.doi.org/10.1128/mBio.01457-20
work_keys_str_mv AT manzanomark kaposissarcomaassociatedherpesvirusdrivesasuperenhancermediatedsurvivalgeneexpressionprograminprimaryeffusionlymphoma
AT guntherthomas kaposissarcomaassociatedherpesvirusdrivesasuperenhancermediatedsurvivalgeneexpressionprograminprimaryeffusionlymphoma
AT juhyunwoo kaposissarcomaassociatedherpesvirusdrivesasuperenhancermediatedsurvivalgeneexpressionprograminprimaryeffusionlymphoma
AT nicholasjohn kaposissarcomaassociatedherpesvirusdrivesasuperenhancermediatedsurvivalgeneexpressionprograminprimaryeffusionlymphoma
AT bartomelizabetht kaposissarcomaassociatedherpesvirusdrivesasuperenhancermediatedsurvivalgeneexpressionprograminprimaryeffusionlymphoma
AT grundhoffadam kaposissarcomaassociatedherpesvirusdrivesasuperenhancermediatedsurvivalgeneexpressionprograminprimaryeffusionlymphoma
AT gottweineva kaposissarcomaassociatedherpesvirusdrivesasuperenhancermediatedsurvivalgeneexpressionprograminprimaryeffusionlymphoma